Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy.
Yanyang NanYu BaiXiaozhi HuKaicheng ZhouTao WuAn ZhuMengyang LiZihan DouZhonglian CaoXumeng ZhangShuwen XuYuanzhen ZhangJun LinXian ZengJiajun FanXuyao ZhangXuebin WangDianwen JuPublished in: Journal for immunotherapy of cancer (2024)
In this study, we demonstrated that IL-33/ST2 was involved in the immunosuppression mechanism of PD-L1 antibody therapy, and blockade by sST2-Fc or anti-PD-L1-sST2 could remodel the inflammatory TME and induce potent antitumor effect, highlighting the potential therapeutic strategies for the tumor treatment by simultaneously targeting IL-33 and PD-L1.